Endoxana (cyclophosphamide) in the treatment of intracerebral malignancy

F. CLIFFORD ROSE, S. N. BHAGWATI, AND WYLIE MCKISSOCK

From Atkinson Morley’s (St. George’s) Hospital, London

The limitations of treatment in malignant growths in the brain are too well known to need comment. In patients with cerebral metastases or astrocytomas of grade III and IV malignancy the survival period is usually to be measured in months. Conventional methods of surgery and radiotherapy have proved unsuccessful. The use of a cytotoxic drug with a selective action on the tumour cells, sparing the normal cells of the body, seems to be an ideal method of treating infiltrating and malignant tumours of the brain. Endoxana (cyclophosphamide), a nitrogen mustard derivative, was chosen because it has a relatively wider margin of safety and a lesser tendency to depression of haemopoietic tissues than many other alkylating agents.

CASE MATERIAL

Fourteen patients, 12 with cerebral gliomas and two with cerebral metastases, admitted to Atkinson Morley’s (St. George’s) Hospital, were given varying courses of this drug.

All cases of malignant glioma were proven histologically, with one exception in which, though there was little doubt macroscopically about the existence of an infiltrating cystic astrocytoma, the histological examination had failed to show definite tumour tissue. Of the two cases of cerebral metastases, one was proved by burr-hole biopsy and the other had widespread metastases elsewhere.

MODE OF USE

After a complete blood count, a test dose of 100 mg. of Endoxana was given intravenously. If this did not produce any undue nausea, vomiting, or depression of the haemopoietic system, the patient was given 400 mg. of Endoxana intravenously daily. Blood counts were performed each day, a close watch being kept on the total number of leucocytes. Intravenous therapy was continued until the total white count fell to about 2,000/c.mm., and the patient was then given 50 mg. of Endoxana orally twice a day, blood counts being carried out less frequently, but usually twice or three times a week.

The dosage of oral Endoxana was varied so as to maintain a total leucocyte count of about 2,000/c.mm. Once the appropriate maintenance dose was established, the patients were discharged from hospital and treated as out-patients, a weekly check on the blood picture being maintained.

On average, about 4 or 5 g. Endoxana had to be given intravenously before the total white blood cell count reached a level of about 2,000/c.mm. Endoxana, 100 mg. orally each day, was sufficient in most cases as a maintenance dose, though in three cases this had to be increased to 200 mg.

RESULTS

The results are set out in Table I. The first patient treated (case 1) was stuporose and died after receiving the drug for only five days. As it was felt that Endoxana would be unlikely to lead to dramatic relief in a few days, it was subsequently given only to patients in good general condition who were not in danger of dying immediately. The remaining 13 cases fulfilled this criterion.

In eight of the 14 cases (cases 1, 2, 3, 4, 5, 7, 9, and 14) no surgical internal decompression was made before the commencement of Endoxana therapy, the tumour having been verified by burr-hole biopsy. Case 4 developed pneumonia due to a resistant staphylococcus, the drug was discontinued, and the patient died within two weeks, there having been no sign of regression of the tumour. Case 7, after being treated with Endoxana for two weeks, developed jaundice which, on investigation, was of the obstructive type. The jaundice cleared within two weeks on discontinuing the drug, and a further course was not given; the patient died six months later from a recurrence of the glioma. The other five cases, after some initial improvement, soon showed obvious signs of continued growth of the tumour and died in periods of one to six months from the time Endoxana therapy began.

CONCOMITANT SURGICAL THERAPY

In one patient (case 11) a moderate amount of tumour was removed through a trephine disc, thus achieving a slight internal decompression. This patient remained in good condition at first, but even-
Enoxana (cyclophosphamide) in the treatment of intracerebral malignancy

Table I

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Initial</th>
<th>Sex</th>
<th>Age (yr)</th>
<th>Type of Tumour</th>
<th>Length of History</th>
<th>Treatment Begun</th>
<th>No. of Doses</th>
<th>Total Given (g)</th>
<th>Survival Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>W.F.</td>
<td>F</td>
<td>55</td>
<td>Astrocytoma (grade IV)</td>
<td>4 mth.</td>
<td>6.1.60</td>
<td>5</td>
<td>1-1</td>
<td>5 days</td>
</tr>
<tr>
<td>2</td>
<td>C.F.</td>
<td>M</td>
<td>62</td>
<td>Astrocytoma (grade III)</td>
<td>4 wk.</td>
<td>25.1.60</td>
<td>95</td>
<td>15-7</td>
<td>4 mth.</td>
</tr>
<tr>
<td>3</td>
<td>M.W.</td>
<td>F</td>
<td>29</td>
<td>Metastases (Ca. colon 2 yr.)</td>
<td>2 mth.</td>
<td>14.2.60</td>
<td>162</td>
<td>18-9</td>
<td>6 mth. Alopecia</td>
</tr>
<tr>
<td>4</td>
<td>V.P.</td>
<td>F</td>
<td>59</td>
<td>Astrocytoma (grade III)</td>
<td>3 mth.</td>
<td>18.2.60</td>
<td>15</td>
<td>3-0</td>
<td>17 days</td>
</tr>
<tr>
<td>5</td>
<td>W.H.</td>
<td>F</td>
<td>57</td>
<td>Astrocytoma (grade III)</td>
<td>2 wk.</td>
<td>2.3.60</td>
<td>70</td>
<td>8-4</td>
<td>3 mth. Alopecia, pigmentation</td>
</tr>
<tr>
<td>6</td>
<td>D.R.</td>
<td>F</td>
<td>68</td>
<td>Astrocytoma (grade III)</td>
<td>3 wk.</td>
<td>16.3.60</td>
<td>40</td>
<td>5-2</td>
<td>4 mth. Frontal lobectomy</td>
</tr>
<tr>
<td>7</td>
<td>W.D.</td>
<td>M</td>
<td>57</td>
<td>Astrocytoma (grade III)</td>
<td>8 wk.</td>
<td>26.3.60</td>
<td>16</td>
<td>5-4</td>
<td>6 mth.</td>
</tr>
<tr>
<td>8</td>
<td>A.R.</td>
<td>F</td>
<td>40</td>
<td>Astrocytoma (grade II)</td>
<td>5 yr.</td>
<td>26.3.60</td>
<td>500</td>
<td>54-0</td>
<td>2½ yr.</td>
</tr>
<tr>
<td>9</td>
<td>J.P.</td>
<td>M</td>
<td>57</td>
<td>Astrocytoma (grade II)</td>
<td>4 mth.</td>
<td>12.4.60</td>
<td>120</td>
<td>18-2</td>
<td>4 mth. Anaemia</td>
</tr>
<tr>
<td>10</td>
<td>M.S.</td>
<td>F</td>
<td>56</td>
<td>Astrocytoma (grade II)</td>
<td>3 wk.</td>
<td>20.4.60</td>
<td>242</td>
<td>32-0</td>
<td>12 mth. Alopecia</td>
</tr>
<tr>
<td>11</td>
<td>V.D.</td>
<td>F</td>
<td>43</td>
<td>Astrocytoma (grade III)</td>
<td>3 wk.</td>
<td>5.5.60</td>
<td>140</td>
<td>16-2</td>
<td>5 mth.</td>
</tr>
<tr>
<td>12</td>
<td>L.G.</td>
<td>F</td>
<td>60</td>
<td>Astrocytoma (grade IV)</td>
<td>5 wk.</td>
<td>9.5.60</td>
<td>20</td>
<td>4-1</td>
<td>1 mth. Anaemia</td>
</tr>
<tr>
<td>13</td>
<td>E.S.</td>
<td>F</td>
<td>64</td>
<td>Astrocytoma (grade III)</td>
<td>4 mth.</td>
<td>17.6.60</td>
<td>100</td>
<td>10-0</td>
<td>4 mth. Anaemia</td>
</tr>
<tr>
<td>14</td>
<td>W.G.</td>
<td>F</td>
<td>62</td>
<td>Metastases (ca. breast 10 yr.)</td>
<td>8 wk.</td>
<td>15.7.61</td>
<td>39</td>
<td>7-6</td>
<td>4 mth. Alopecia</td>
</tr>
</tbody>
</table>

Nausea and vomiting were observed in about a third of the cases for the first two or three days, but could be controlled with Dramamine or Largactil. Excessive leucopenia (below 1,600 per c.mm.) occurred in five cases, but was corrected without difficulty by the temporary withholding of the drug; when properly stabilized, these patients continued to have Enoxana without any excessive leucopenic effect. Three cases showed evidence of iron-deficiency anaemia, which responded to iron therapy. The platelet count was not affected. One patient developed obstructive jaundice which cleared up completely in two weeks after stopping the Enoxana.

The commonest complication was alopecia; nearly all the patients had their heads shaved for surgical procedures and subsequent growth of hair was extremely slow so that it was only after four to five months that hair started growing. Neither case 8 nor case 10 had regained their normal growth of hair after as long a period as 12 months. In two cases in which only a short course of Enoxana was given, the hair soon began to grow again.

Discussion

Because of the hazards of fractionated intra-arterial injection (Klopp, Alford, Bateman, Berry, and
Endoxana is effective when given systemically. An earlier report (Simon, 1959) on the use of Endoxana in cerebral neoplasms stated that the drug 'was invariably well tolerated' and that if it was given 'following surgical excision, the prognosis for survival is better'. Our results do not substantiate either of these statements. The only patient surviving longer than eight months without any signs of increased intracranial pressure and the result is comparable to the usual progress of a glioma of this grade of malignancy, and the result is similar to the usual progress of gliomas that have been treated when the drug was administered systemically.

Intracranial pressure and the invariably well tolerated side-effects included nausea, vomiting, marked alopecia, iron-deficiency anaemia, and severe leucopenia; the last disappeared when the drug was discontinued. In one case, transient obstructive jaundice occurred.

In this series the systemic administration of Endoxana had no therapeutic effect.

We are grateful to Ward Blenkinsop Ltd. for supplying Endoxana.

REFERENCES


SUMMARY

Endoxana, a nitrogen mustard derivative, was given systemically in 14 cases of intracerebral tumour; 12 of these tumours were gliomas and two cerebral metastases.

All the patients have died from the continued growth of the tumour. Only one patient survived longer than 12 months, and in this case the tumour was histologically of low malignancy.

Side-effects included nausea, vomiting, marked alopecia, iron-deficiency anaemia, and severe leucopenia; the last disappeared when the drug was discontinued. In one case, transient obstructive jaundice occurred.

In this series the systemic administration of Endoxana had no therapeutic effect.

We are grateful to Ward Blenkinsop Ltd. for supplying Endoxana.

REFERENCES


The August 1964 Issue

The August 1964 issue contains the following papers:

Epidemiology and mental disorder: A review

MICHAEL SHEPHERD and BRIAN COOPER

Cognitive deficit related to seizure pattern in centrencephalic epilepsy

DOREEN KIMURA

Observations on colour agnosia

M. KINSBOROUGH and ELIZABETH K. WARRINGTON

The effect of hypnotic anaesthesia on cortical responses

A. M. HALLIDAY and A. A. MASON

Spinal cord compression by extramedullary haematopoiesis in myelosclerosis

A. APPLEBY, G. A. BATSON, L. P. LASSMAN, and CHARLES A. SIMPSON

Central pontine myelinolysis

J. L. CHASON, J. W. LANDERS, and J. E. GONZALEZ

Angiography study of the middle cerebral artery in chronic infantile hemiplegia

MARK DYKEN

Superficial haemosiderosis of the central nervous system

B. E. TOLMINSON and JOHN N. WALTON

Electroencephalographic changes associated with cerebellar hemisphere tumours

PAUL DYKEN, HARRY L. MANNING, and PHILIP WHITE

Myasthenia gravis with hypergammaglobulinaemia and antibodies

H. J. G. H. OOSTERHUIS, H. VAN DER GELD, T. E. W. FELTKAMP, and F. PEETOOM

Clinical and electrophysiological study of the pattern of conduction times in the distribution of the sciatic nerve

M. M. GASSEL and W. TROJABORG

Book reviews

Copies are still available and may be obtained from the PUBLISHING MANAGER, BRITISH MEDICAL ASSOCIATION, TAVISTOCK SQUARE, W.C.1, price 18s. 6d.
Endoxana (cyclophosphamide) in the treatment of intracerebral malignancy
F. Clifford Rose, S. N. Bhagwati and Wylie Mckissock

*J Neurol Neurosurg Psychiatry* 1964 27: 470-472
doi: 10.1136/jnnp.27.5.470

Updated information and services can be found at:
http://jnnp.bmj.com/content/27/5/470.citation

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/